WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530584

CAS#: Unknown (4/23/2017)

Description: AM-0466 is a potent and selective NaV1.7 Inhibitor (Nav 1.7 IC50 = 21 nM; Nav 1.5 IC50 =>30.0 uM. PXR = 22% @10 uM; CYP 2C9 IC50 = 4.6 uM; CYP3A4 TDI IC50 =>50.0 uM.). AM-0466 Affords Robust in Vivo Activity. AM-0466 demonstrated robust pharmacodynamic activity in a NaV1.7-dependent model of histamine-induced pruritus (itch) and additionally in a capsaicin-induced nociception model of pain without any confounding effect in open-field activity.

Chemical Structure

CAS# Unknown (4/23/2017)

Theoretical Analysis

MedKoo Cat#: 530584
Name: AM-0466
CAS#: Unknown (4/23/2017)
Chemical Formula: C27H19F3N4O4S
Exact Mass: 552.1079
Molecular Weight: 552.5282
Elemental Analysis: C, 58.69; H, 3.47; F, 10.32; N, 10.14; O, 11.58; S, 5.80

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: AM-0466; AM 0466; AM0466.

IUPAC/Chemical Name: 1-(3-methoxy-2'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-2-oxo-N-(pyrimidin-2-yl)-1,2-dihydroquinoline-6-sulfonamide


InChi Code: InChI=1S/C27H19F3N4O4S/c1-38-24-16-17(20-5-2-3-6-21(20)27(28,29)30)7-10-23(24)34-22-11-9-19(15-18(22)8-12-25(34)35)39(36,37)33-26-31-13-4-14-32-26/h2-16H,1H3,(H,31,32,33)

SMILES Code: O=S(NC1=NC=CC=N1)(C2=CC=C(N(C3=CC=C(C4=CC=CC=C4C(F)(F)F)C=C3OC)C(C=C5)=O)C5=C2)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 552.5282 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Graceffa RF, Boezio AA, Able J, Altmann S, Berry LM, Boezio C, Butler JR,
Chu-Moyer M, Cooke M, DiMauro EF, Dineen TA, Feric Bojic E, Foti RS, Fremeau RT
Jr, Guzman-Perez A, Gao H, Gunaydin H, Huang H, Huang L, Ilch C, Jarosh M,
Kornecook T, Kreiman CR, La DS, Ligutti J, Milgram BC, Lin MJ, Marx IE, Nguyen
HN, Peterson EA, Rescourio G, Roberts J, Schenkel L, Shimanovich R, Sparling BA,
Stellwagen J, Taborn K, Vaida KR, Wang J, Yeoman J, Yu V, Zhu D, Moyer BD, Weiss
MM. Sulfonamides as Selective Na(V)1.7 Inhibitors: Optimizing Potency,
Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone
(AM-0466) that Affords Robust in Vivo Activity. J Med Chem. 2017 Apr 20. doi:
10.1021/acs.jmedchem.6b01850. [Epub ahead of print] PubMed PMID: 28324649.

Additional Information

Approximately 2% of the world’s population is affected by neuropathic pain.2 In the United States alone, it was estimated that the costs attributed to pain were approximately $600 billion annually.3 Currently, treatments for pain include opioids, antidepressants, anticonvulsants, and analgesics, which are often used in combination. These therapeutic approaches have several shortcomings such as limited efficacy, unwanted side effects including sedation and coordination impairment, and possible addiction. Additionally, it is estimated that only 50% of the patients can obtain satisfactory relief with current therapies.